Rituximab in ANCA-Associated Vasculitis

被引：43

作者：

Hassan, Romina I. ^{[1
]}

Gaffo, Angelo L. ^{[2
,3
]}

机构：

[1] JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina

[2] Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA

[3] Univ Alabama Birmingham, Div Rheumatol & Clin Immunol, 1825 Univ Blvd,SHEL 306, Birmingham, AL 35294 USA

来源：

CURRENT RHEUMATOLOGY REPORTS | 2017年 / 19卷 / 02期

关键词：

Rituximab; Vasculitis; ANCA; Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); Eosinophilicgranulomatosiswith polyangiitis (EGPA); WEGENERS-GRANULOMATOSIS; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; CYCLOPHOSPHAMIDE; INDUCTION; REMISSION; THERAPY; MAINTENANCE; MANAGEMENT; RELAPSES;

D O I：

10.1007/s11926-017-0632-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of Review The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). Recent Findings A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA). Summary Rituximab is a therapeutic option to induce and maintain remission in patients with AAV.

引用

页数：8

共 50 条

[41] The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)
Daikeler, Thomas
Kistler, Andreas D.
Martin, Pierre-Yves
Vogt, Bruno
Huynh-Do, Uyen
SWISS MEDICAL WEEKLY, 2015, 145
[42] Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial
Geetha, Duvuru
Dua, Anisha
Yue, Huibin
Springer, Jason
Salvarani, Carlo
Jayne, David
Merkel, Peter
ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (02) : 223 - 232
[43] Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
Suppiah, Ravi
Hadden, Robert D. M.
Batra, Rajbir
Arden, Nigel K.
Collins, Michael P.
Guillevin, Loic
Jayne, David R. W.
Luqmani, Raashid A.
RHEUMATOLOGY, 2011, 50 (12) : 2214 - 2222
[44] ANCA-Associated Vasculitis: An Update
Almaani, Salem
Fussner, Lynn A.
Brodsky, Sergey
Meara, Alexa S.
Jayne, David
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
[45] Biomarkers in ANCA-Associated Vasculitis
Lally, Lindsay
Spiera, Robert F.
CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (10)
[46] ANCA-associated vasculitis
Holle, J. U.
INTERNIST, 2015, 56 (01): : 41 - 52
[47] The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis
Free, Meghan E.
Falk, Ronald J.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (09): : 2551 - 2553
[48] Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts
Pagnoux, C.
Carette, S.
Khalidi, N. A.
Walsh, M.
Hiemstra, T. F.
Cuthbertson, D.
Langford, C.
Hoffman, G.
Koening, C. L.
Monach, P. A.
Moreland, L.
Mouthon, L.
Seo, P.
Specks, U.
Ytterbere, S.
Westman, K.
Hoglund, P.
Harper, L.
Flossmann, O.
Luqmani, R.
Savage, C.
Rasmussen, N.
de Groot, K.
Tesar, V.
Jayne, D.
Merkel, P. A.
Guillevin, L.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (02) : S77 - S83
[49] ANCA-associated vasculitis
Holle, J. U.
INTERNIST, 2015, 56 (01): : 41 - 52
[50] ANCA-Associated Vasculitis: Practical Issues in Management
Roper, Tayeba
Salama, Alan David
INDIAN JOURNAL OF NEPHROLOGY, 2024, 34 (01) : 6 - 23

← 1 2 3 4 5 →